CONTACT
+91 80 2808 2808
ContactUs.BBL@biocon.com
About Us
Overview
Our work in Biosimilars
Board of Directors
Executive Leadership Team
Our Stories
Biocon Biologics Malaysia
Scientific Publications
Awards & Recognition
Our Legacy
Our Business
Global Biosimilars Portfolio
Oncology
Immunology
Diabetology
Ophthalmology
Bone Health & Others
Our Products
Global
India
Partners
Global Footprint
Our Capabilities
Research & Development
Quality & Compliance
Global Scale Manufacturing
Investors
Newsroom
Press Releases
Company Statements
Our Stories
Media Contacts
Careers
Working With Us
Now Hiring
Contact Us
Company Statements 2021
Biocon Biologics
/
News – Posts
/
Company Statements
/
Company Statements 2021
Biocon Biologics Insulin Manufacturing Facility in Malaysia Completes U.S. FDA (PAI) Inspection
Sat, 25-Sep-2021
Posted by: Biocon Biologics
No Comments
Kiran Mazumdar-Shaw Joins Board of Trustees of Memorial Sloan Kettering Cancer Center, U.S.
Wed, 28-Apr-2021
Posted by: Biocon Biologics
No Comments
Biocon Biologics and Viatris Receive European Commission Approval for Biosimilar Bevacizumab
Mon, 26-Apr-2021
Posted by: Biocon Biologics
No Comments
Biocon Biologics and Viatris Receive European Commission Approval for Kixelle, Biosimilar Insulin Aspart
Fri, 12-Feb-2021
Posted by: Biocon Biologics
No Comments